FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| washington, D.C. 20049 | OMB APPROVAL | | | |
|--|--------------------------|--------|--|--|
| STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP | OMB Number: | 3235-0 | | |
| | Estimated average burden | | | |

| OMB Number: | 3235-0287 |
|---------------------|-----------|
| Estimated average I | burden |
| hours per response: | 0.5 |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| | | | | | | | . , | | | | | | | | | | | |
|--|--|---------|------------------------------|--|---|--|--|----------|---|------------|------------------------|---|--|--|---------------------------------------|----------------------|--------------|------------------|
| 1. Name and Address of Reporting Person* | | | | 2. Issuer Name and Ticker or Trading Symbol NEKTAR THERAPEUTICS [NKTR] | | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | | | | |
| ROBIN HOWARD W | | | | interior in the latest | | | | | | | | X | Dire | ctor | 10% | Owner | | |
| (Last) | (F | rst) (| (Middle) | | | | | | | | | | | X | Offic belo | er (give title w) | Othe belo | r (specify v) |
| C/O NEKTAR THERAPEUTICS | | | | 3. Date of Earliest Transaction (Month/Day/Year) 05/16/2017 | | | | | | | | President & CEO | | | | | | |
| 455 MISSION BAY BOULEVARD SOUTH | | | | | | | | | | | | | | | | | | |
| (Street) | | | | | 4. If | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | |
| SAN | C. C. | A 9 | 94158 | | | | | | | | | | X | Forn | n filed by One | ne Reporting Person | | |
| FRANCI | SCO | | | | | | | | | | | | Form filed by More than One Reporting Person | | | | | |
| (City) | (S | tate) (| (Zip) | | | | | | | | | | | | | | | |
| | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | | |
| 1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day) | | | | Execution Date, | | 3. 4. Securities Acquired (A) of Transaction Code (Instr. 8) 4. Securities Acquired (D) (Instr. 3, 4 and 1) (Instr. 3, 4 and 1 | | | and 5) Secur Benef | | icially d Following | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Ownership | | | | | |
| | | | | | | | | Code | v | Amount | (A) (D) | or Pri | e | Trans | action(s) 3 and 4) | | (Instr. 4) | |
| Common Stock 05/16/20 | | | 2017 |)17 | | S | | 8,388(1) | D | D \$19.550 | | 160,884 | | D | | | | |
| Common Stock | | | | | | | | | | | | | | 410 | I | by spouse | | |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | rative Conversion Date Execution Date, if any | | 4. Transa Code (8) | | Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Date Expiration Date | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4) Amount or Number of Title Shares | | unt ber | | 9. Number of derivative Securities Beneficially Owned Following Reported Transactions (Instr. 4) | Ownership Form: Direct (D) or Indirect (I) (Instr. 4 | Beneficial Ownership (Instr. 4) | | | |

Explanation of Responses:

- 1. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- 2. This transaction was executed in multiple trades at prices ranging from \$19.31 to \$19.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

Remarks:

Mark A. Wilson, Attorney-in-05/18/2017 **Fact**

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.